Abbott launches Crohn's disease podcasts

Share this article:

Abbott has launched a series of podcasts, or “Crohn's Casts,” offering information and insights into Crohn's disease.

The podcasts – which feature clinical information from practicing health professionals and testimony from Crohn's sufferers – are located on an unbranded website, explained Michelle Johnson, manager, public affairs, at Abbott, though patients have “opportunities to get additional information,” she said. 

“This is the first time [Abbott] has used podcasts to create awareness for a disease,” said Johnson, adding that the company will “evaluate results when the series is finished, and assess the feedback.”

Abbott markets Humira (adalimumab), a tumor necrosis factor blocker, for the treatment of Crohn's disease. A link to the Crohn's Casts website can be found on the product page for Humira or click here.

The Crohn's disease podcasts are a valuable source of information for both patients and physicians, since the general public isn't as familiar with the disease, noted Johnson.

“People with Crohn's disease suffer from symptoms they don't necessarily want to talk about,” like digestive difficulties, said Johnson. Crohn's disease is most often diagnosed in patients between the ages of 15 and 35 – another reason podcasts make sense, according to Johnson. “People are going online, and they are looking for trusted resources,” she said.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...